Dennis Selkoe

Dr. Selkoe is a member of the Board of Directors for Prothena Corporation; for his service, he receives cash compensation and holds public equity. Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies. The company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease (PD). The research will study a unique new mouse model of PD that has unique features of a delayed, progressive PD-like motor syndrome affecting males more than females and including resting tremor, gait and limb deficits partly responsive to L-DOPA. The research will characterize the mouse model's faithfulness to PD and its advantages over earlier mouse models and then explore two entirely novel treatment strategies. The research and the company have an overlapping interest in the treatment of PD and, if the research is successful, it has the potential to influence the company’s development efforts. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee determined that the conflict could be managed with the implementation of an FCOI management plan.